Trius Therapeutics Report issue

Contributed to NME For profit Phase 1 Phase 3
Founded: San Diego CA United States (2004)
Status: Acquired by Cubist (2013) → now Merck (2014)

Organization Overview

First Clinical Trial
2008
NCT00671814
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Tris Pharma | Trius

Active Ingredients

Drugs in Phase 3 Trials (3)

amphetamine (Adderall) (1 trial)

linezolid (zyvox) (3 trials)

tedizolid phosphate (sivextro) (18 trials)

Drugs in Phase 1 Trials (2)

moxifloxacin (avelox) (1 trial)

tyramine (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Abscess (Phase 2)

Attention Deficit Disorder with Hyperactivity (Phase 3)

Bacterial Infections (Phase 3)

Cellulitis (Phase 2)

Communicable Diseases (Phase 3)

Erysipelas (Phase 2)

Infections (Phase 3)

Liver Diseases (Phase 1)

Renal Insufficiency (Phase 1)

Skin Diseases (Phase 2)

Skin Diseases, Bacterial (Phase 3)

Skin Diseases, Infectious (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 5